Table 1 Patient characteristics and association with RANK and RANKL expression by immunohistochemistry
From: RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy
Pregnant ( n = 65) | Nonpregnant ( n = 130) | Mean RANKL H-score on primary tumor ( P value) a | Mean RANK H-score on primary tumor ( P value) | |
|---|---|---|---|---|
Tumor size | ||||
≤ 2 cm | 26 (40%) | 52 (40%) | 28.21 | 10.08 |
> 2 cm or pTxb | 38 (60%) | 78 (60%) | 8.63 (P = 0.01) | 17.50 (P = 0.15) |
Nodal status | ||||
Negative | 28 (43.1%) | 56 (43.1%) | 24.51 | 14.12 |
Positive or pNxb | 37 (56.9%) | 74 (56.9%) | 9.04 (P = 0.03) | 14.36 (P = 0.96) |
Histological gradec | ||||
I | 4 (6.2%) | 4 (3.1%) | 70 | 7.5 |
II | 21 (32.3%) | 43 (33.1%) | 29.92 | 3.82 |
III | 36 (55.3%) | 68 (52.3%) | 6.25 (P < 0.001) | 22.2 (P < 0.001) |
ER | ||||
Positive | 43 (66.1%) | 96 (73.8%) | 20.43 | 5.43 |
Negative | 22 (33.9%) | 34 (26.2%) | 5 (P = 0.05) | 36.71 (P < 0.001) |
PgR | ||||
Positive | 42 (64.6%) | 85 (65.4%) | 24.11 | 5.09 |
Negative | 23 (35.4%) | 45 (34.6%) | 0.67 (P < 0.001) | 31.76 (P < 0.001) |
HER2 | ||||
Positive | 11 (16.9%) | 23 (17.7%) | 3.18 | 10.82 |
Negative | 54 (83.1%) | 107 (82.3%) | 18.79 (P = 0.1) | 14.95 (P = 0.53) |
PIK3CA mutationd | ||||
Yes | 10 (15.4%) | 27 (20.7%) | 24.03 | 6.3 |
No | 52 (84.7%) | 102 (79.3%) | 12.47 (P = 0.18) | 15.63 (P = 0.13) |